Physician profile
Jillian E Haney
NPI 1710505524
$5,220.12
in general payments reported to CMS, 2019-2025
43 companies · $21.38 in 2025
The $21.38 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,798 · 2022: $1,776 · 2023: $1,356 · 2024: $269 · 2025: $21.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.01 | 2021-2025 | |
| Novo Nordisk INC | $578.28 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $386.74 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $259.01 | 2021-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.59 | 2021-2024 | Jardiance, Tradjenta |
| Amgen INC. | $251.66 | 2021-2023 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $236.67 | 2021-2023 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $228.98 | 2021-2023 | Farxiga, Breztri |
| Astellas Pharma US INC | $225.86 | 2021-2023 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $170.54 | 2023-2024 | Gemtesa |
| Pfizer INC. | $140.37 | 2021-2024 | |
| Amarin Pharma, INC. | $124.41 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $124.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.94 | 2021-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $105.39 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.